Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2003
10/22/2003EP1353691A2 Molecular antigen array presenting amyloid beta
10/22/2003EP1353684A2 Use of inhibitors of dipeptidypeptidase iv (ec 3.3.14.5) and aminopeptidase n (ec 3.4.11.2) for the treatment of neurodegeneration induced by ischaemia
10/22/2003EP1353675A2 New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
10/22/2003EP1353672A2 Synthesis of 3-amino-thalidomide and its enantiomers
10/22/2003EP1353671A1 Neurotrophic tacrolimus analogs
10/22/2003EP1353670A2 Use of chromanes
10/22/2003EP1353665A1 Treatment of depression
10/22/2003EP1353659A1 Use of neurotoxic substances in producing a medicament for treating joint pains
10/22/2003EP1353656A2 Method for treating stress or tension
10/22/2003EP1353655A2 Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
10/22/2003EP1353650A2 Process for preparing non-hygroscopic sodium valproate composition
10/22/2003EP1219621B1 Azaindolizinone derivatives and cognitive enhancers comprising the same as effective components
10/22/2003EP1196135B1 Compositions comprising organosiloxane resins for delivering oral care substances
10/22/2003EP1183236B1 Cinnamoylaminoalkyl-substituted benzenesulfonamide derivatives
10/22/2003EP1177167B1 High purity (1r, 2s, 4r)-(-)-2-[(2'-(n,n-dimethylamino)-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof, process for the preparation of these compounds and medicaments containing them.
10/22/2003EP1164996B1 Transdermal therapeutic system with nicotine and addition of monoterpene ketones
10/22/2003EP1150961B1 Pyrazolecarboxylic acid derivatives, their preparation, pharmaceutical compositions containing them
10/22/2003EP1149076B1 O-thiocarbamoyl-aminoalkanol compounds, their pharmaceutically acceptable salts and process for preparing the same
10/22/2003EP1144386B1 Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament
10/22/2003EP1140105B1 Controlled release galantamine composition
10/22/2003EP1140031B1 Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
10/22/2003EP1104446B1 Biologically active fraction of vegetable melanin, process for its production and its use
10/22/2003EP1089993B1 5-ht1f agonists
10/22/2003EP1084122B1 Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity
10/22/2003EP1083168B1 Prostaglandin derivative
10/22/2003EP1056754B1 Phosphate derivatives of diaryl 1,3,4-oxadiazolone
10/22/2003EP1056744B1 6,9-disubstituted 2- trans-(4- aminocyclohexyl) amino]purines
10/22/2003EP1056460B1 Pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system
10/22/2003EP1053244B1 Glycosidation of 4,5-epoxymorphinan-6-ols
10/22/2003EP1041984B1 Pharmaceutical composition for oral administration
10/22/2003EP1032566B9 Method for the preparation of citalopram
10/22/2003EP1003749B1 8-SUBSTITUTED-9H-1,3-DIOXOLO/4,5-h/2,3/BENZODIAZEPINE DERIVATES, AS AMPA/KAINATERECEPTOR INHIBITORS
10/22/2003EP0980368B1 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one derivatives and their use as 5-ht4 ligands
10/22/2003EP0927184B1 3-substituted pyrido 4',3':4,5]thieno 2,3-d]pyrimidine derivatives, their preparation and their use
10/22/2003EP0892802B1 Spiro(cyclopent(b)indole-piperidines) and n-phenyl-hydrazon intermediates for their preparation, both being acetylcholinesterase and mao inhibitors
10/22/2003EP0815221B1 A novel growth factor and a genetic sequence encoding same
10/22/2003CN1451045A IFN-alpha homologues
10/22/2003CN1451043A Dual specificity antibodies and methods of making and using
10/22/2003CN1451007A Adenosine A2A receptor antagonists
10/22/2003CN1451006A I-[alkyl] 1-[(heteroaryl) alkyl] and 1 [(aryl) alkyl] 7-pyridinyl-imidazo [1,2-a] pyrimidin-5(1h)-one derivatives
10/22/2003CN1451005A 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
10/22/2003CN1451004A 7-oxo pyridopyrimidines
10/22/2003CN1451002A Indole derivatives for treating central nervous system disease
10/22/2003CN1450999A Novel piperazine derivatives
10/22/2003CN1450998A Inhibitors of copper-containing amine oxidases
10/22/2003CN1450997A Inhibitors of copper-containing amine oxidases
10/22/2003CN1450908A Neurotoxic oligomers
10/22/2003CN1450907A Beta glycan as an inhibin receptor and uses thereof
10/22/2003CN1450894A Phenylethylamines and condensed rings variants as prodrugs of catecholamines and their use
10/22/2003CN1450066A Porphyrin derivate with macrosubstituent, preparation process thereof and use as small molecule antioxidant
10/22/2003CN1449810A Traditional Chinese medicine for treating brain dysfunction
10/22/2003CN1449788A Nutrient extract for dispelling effects of alcohol
10/22/2003CN1449754A Edaravone medicine composition and preparation thereof
10/22/2003CN1449750A Gabapentin slow -released composition
10/22/2003CN1449745A Coated solid hyponotic
10/22/2003CN1125070C Pyrrolo [2,3-d] pyrmidine compounds, and compositions and use thereof
10/22/2003CN1125064C 3-pyridyl enantiomers and their use as analgesics
10/22/2003CN1125062C Dihydrobenzofuran and related compounds useful useful as anti-inflammatory agents
10/22/2003CN1125058C Crystalline dibentothiazepine derivatives and its use as antipsychotic agent
10/22/2003CN1125054C Novel imidazolidine derivatives, their preparation their use and pharmaceutical preparations comprising them
10/22/2003CN1125052C Substituted isoquinoline derivatives and their use as anticonvulsants
10/22/2003CN1125044C Novel prostaglandin synthase inhibitors
10/22/2003CN1124850C Process for preparing medicine to treat treat facial paralysis
10/22/2003CA2424577A1 Use of huntingtin and related compounds for modulating cell survival
10/21/2003US6635786 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use
10/21/2003US6635764 Urea compounds that are muscarinic receptor antagonists and agonists, administering to the mammal the urea compound to treat urinary incontinence, chronic pulmonary obstructive disease, asthma, hyper salivation, blurred vision etc.
10/21/2003US6635762 Monocyclic-7H-pyrrolo[2,3-d]pyrimidine compounds, compositions, and methods of use
10/21/2003US6635744 Substantially pure fibroblast growth factor homologous factor-4 polypeptide having specified amino acid sequence; diagnosis and treatment of neurodegenerative and neoplastic disorders
10/21/2003US6635680 Controlled release pellet formulation
10/21/2003US6635675 Method of treating chronic fatigue syndrome
10/21/2003US6635673 1-Aminomethyl-3,4-dimethyl-cyclopentyl acetic acid; epilepsy; neurodegenerative, neuropathological and gastrointestinal disorders; depression, anxiety, panic, pain
10/21/2003US6635669 Kinase inhibitor; benign prostatic hyperplasia
10/21/2003US6635661 Heterocyclic analgesic compounds and methods of use thereof
10/21/2003US6635653 Spiropyrazole compounds
10/21/2003US6635652 Senile dementia and Alzheimer's disease
10/21/2003US6635650 Such as N-(2-(7-(2-((8-(2-(acetyl-amino)ethyl)-2-naphthyl) oxy)ethoxy)-1-napthyl)ethyl)acetamide for treating or preventing melatoninergic disorders
10/21/2003US6635648 Combination therapy using sympathetic nervous system antagonists and endothelin antagonists
10/21/2003US6635647 Decahydro-isoquinolines
10/21/2003US6635645 2,5,-diazabicyclo[2.2.1]heptane derivatives, their preparation and therapeutic uses
10/21/2003US6635644 Pyrimido(1,6-b)pyridazine derivatives used as p38 inhibitors a mammalian protein kinase is involved in cell proliferation, cell death and response to extracellular stimuli
10/21/2003US6635642 Poly(ADP-ribose) polymerase inhibitors; tissue damage treatment
10/21/2003US6635640 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
10/21/2003US6635639 Use of N-alkylamino-heterocylic compounds for the treatment of migraine
10/21/2003US6635635 Benzothiadiazine compounds
10/21/2003US6635632 Alzheimer's disease
10/21/2003US6635621 Alpha amino acid amide derivatives; reducing cathepsins B, L, S and/or K activity
10/21/2003US6635619 Amino acid sequence 88, 96, 97, 98, 99 or 100; increasing serum and tissue levels of active component
10/21/2003US6635616 Laminin 15
10/21/2003US6635483 Antisense polynucleotide targeted to a nucleic acid encoding the gene, thereby suppressing its expression; cDNA encapsulated in liposome; use as antitumor, anticarcinogenic or antiapoptotic; Alzheimer's disease
10/21/2003US6635284 Delivery of multiple doses of medications
10/21/2003US6635270 NMDA receptor agonist pharmaceutical compositions
10/21/2003US6635250 Use of certain metalloproteinase inhibitors for treating nerve disorders mediated by nucleus pulpsus
10/21/2003US6635237 Pharmaceutical composition based on cocaethylene and use thereof for treating psychoactive substance dependence
10/21/2003CA2310318C Pseudopolymorphic forms of 2-[2-[4-[bis (4-fluorophenyl) methyl]-1-piperazinyl] ethoxy]acetic acid dihydrochloride
10/21/2003CA2240136C Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
10/21/2003CA2237401C Novel intermediates and their use to prepare n,n'-bridged bisindolylmaleimides
10/21/2003CA2049733C 6,7-dihydro-3-phenyl-1,2-benzisoxazol-4(5h)-ones and -ols, a process for their preparation and their use as medicaments
10/16/2003WO2003085131A2 Diagnostic and therapeutic use of vault polynucleotides and proteins for neurodegenerative diseases
10/16/2003WO2003085110A2 Oligomeric compounds for the modulation hif-1alpha expression
10/16/2003WO2003084984A1 Heterocyclic amides with alpha-4 integrin antagonist activity
1 ... 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 ... 1833